ARISE study: Study Design and Baseline Characteristics for a Phase 2 Trial of the Anti-Tau Antibody ABBV-8E12 in Progressive Supranuclear Palsy
Objective: This double-blind, placebo-controlled phase 2 study (M15-562 ARISE study, NCT02985879) assesses the safety and efficacy of ABBV-8E12 treatment in patients with progressive supranuclear palsy…Striatal FP-CIT SPECT findings for progressive supranuclear palsy subtypes
Objective: In our previous study FP-CIT SPECT (FP-CIT) in progressive supranuclear palsy-Parkinsonism (PSP-P) revealed higher anterior striatal accumulation, and PSP- Richardson’s syndrome (PSP-RS) revealed lower…Motor and cognitive deficits in a mouse model of tauopathy with tau isoforms imbalance: Potential therapeutic strategies
Objective: This work investigates motor phenotypes and neurochemical changes in a mouse model of tauopathy linked to tau mis-splicing. We sought to validate a potential…An atutopsy case of argyrophilic grain disease, clinically presenting with Parkinson dementia
Objective: We here reported argyrophilic grain disases (AGD) with clinical diagnosis of Parkinson dementia. Background: AGD is a four-repeat tauopathy and its accumulation (argyrophilic grain…Analysis of Tau Burden and Distribution on the Spectrum of PSP Subtypes
Objective: The aim of this study was to assess the previous hypothesis about relationship between clinical spectrum of Progressive Supranuclear Palsy (PSP) and tau burden…A panel of CSF and plasma biomarkers reveals novel biological insights into atypical parkinsonian syndromes
Objective: Our study aims to identify diagnostic markers of atypical parkinsonian disorders that offer novel insights into these conditions. In particular, we wish to use…Predictors and biomarkers of pain in newly diagnosed Parkinson’s disease patients during a two-year follow-up
Objective: To identify clinical characteristics, predictors and biomarkers of pain at baseline and after a two-year follow-up period in newly diagnosed drug-naïve Parkinson's Disease (PD)…Salivary Alpha-Synuclein and tau in Parkinson’s Disease and Progressive Supranuclear Palsy
Objective: The aim of this study is to measure alpha-synuclein (a-syn) total, a-syn oligomers (a-syn olig) and total tau protein concentration in the saliva of…Tau and α-synuclein autoantibodies as potential biomarkers for Parkinson’s and Alzheimer’s diseases
Objective: To investigate the value of the naturally occurring serum AIAs of α-synuclein (α-syn) and tau, proteins as potential biomarker for diagnosis of PD in…IGF-1 levels are associated with CSF pathology and executive dysfunction in de novo Parkinson’s disease patients
Objective: To investigate whether serum insulin-like growth factor-1 (IGF-1) is associated with clinical-neuropsychiatric, imaging and CSF markers of PD pathology in patients with early, drug-naïve…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 16
- Next Page »